Madrigal Pharmaceuticals Inc (MDGL)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track

Stock chart
Ticker: MDGL Exchange: NAS


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Earnings
 
Value bought

Past 90 days

 
Value sold

Past 90 days

 
Net insiders buying

Past 90 days

 
Trades (buy and sell)

Past 90 days

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
75 -0.0%
330.23
USD 24,767 		75 -0.0% 330.23 USD 24,767
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
967 -0.3%
329.86
USD 318,975 		967 -0.3% 329.86 USD 318,975
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
400 -0.1%
328.68
USD 131,472 		400 -0.1% 328.68 USD 131,472
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
1,000 -0.3%
327.63
USD 327,627 		1,000 -0.3% 327.63 USD 327,627
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
800 -0.2%
325.63
USD 260,501 		800 -0.2% 325.63 USD 260,501
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
900 -0.3%
324.69
USD 292,218 		900 -0.3% 324.69 USD 292,218
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
1,649 -0.5%
323.47
USD 533,394 		1,649 -0.5% 323.47 USD 533,394
2025-03-14 2025-03-13 S Sale

CRAVES FRED B

Non-Executive Director
1,951 -0.5%
322.45
USD 629,100 		1,951 -0.5% 322.45 USD 629,100
2025-03-14 2025-03-12 S Sale

CRAVES FRED B

Non-Executive Director
200 -0.1%
334.97
USD 66,994 		200 -0.1% 334.97 USD 66,994
2025-03-14 2025-03-12 S Sale

CRAVES FRED B

Non-Executive Director
800 -0.2%
333.66
USD 266,926 		800 -0.2% 333.66 USD 266,926
2025-03-14 2025-03-12 S Sale

CRAVES FRED B

Non-Executive Director
2,382 -0.7%
332.38
USD 791,726 		2,382 -0.7% 332.38 USD 791,726
2025-03-14 2025-03-12 S Sale

CRAVES FRED B

Non-Executive Director
2,759 -0.8%
331.36
USD 914,221 		2,759 -0.8% 331.36 USD 914,221
2025-03-14 2025-03-12 S Sale

CRAVES FRED B

Non-Executive Director
1,587 -0.4%
330.54
USD 524,560 		1,587 -0.4% 330.54 USD 524,560
2025-03-12 2025-03-10 PS Planned sale

Dier Mardi

SVP and CFO

Officer
258 -2.4%
323.04
USD 83,344 		258 -2.4% 323.04 USD 83,344
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,412 -27.5%
344.76
USD 486,797 		1,412 -27.5% 344.76 USD 486,797
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
4,701 -47.8%
343.85
USD 1,616,429 		4,701 -47.8% 343.85 USD 1,616,429
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,077 -9.9%
342.90
USD 369,300 		1,077 -9.9% 342.90 USD 369,300
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,043 -8.7%
341.84
USD 356,537 		1,043 -8.7% 341.84 USD 356,537
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,657 -12.2%
340.75
USD 564,627 		1,657 -12.2% 340.75 USD 564,627
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
400 -2.9%
339.68
USD 135,874 		400 -2.9% 339.68 USD 135,874
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,146 -7.6%
338.09
USD 387,452 		1,146 -7.6% 338.09 USD 387,452
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,777 -10.5%
336.78
USD 598,457 		1,777 -10.5% 336.78 USD 598,457
2025-03-07 2025-03-05 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
900 -5.0%
335.15
USD 301,631 		900 -5.0% 335.15 USD 301,631
2025-03-05 2025-03-03 PS Planned sale

Dier Mardi

SVP and CFO

Officer
774 -10.1%
323.54
USD 250,417 		774 -10.1% 323.54 USD 250,417
2025-03-05 2025-03-03 S Sale

Dier Mardi

SVP and CFO

Officer
1,187 -13.4%
325.89
USD 386,831 		1,187 -13.4% 325.89 USD 386,831
2025-03-05 2025-03-03 PS Planned sale

Kelley Shannon T

General Counsel

Officer
415 -5.4%
335.00
USD 139,025 		415 -5.4% 335.00 USD 139,025
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
563 -6.1%
335.00
USD 188,605 		563 -6.1% 335.00 USD 188,605
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
100 -1.1%
329.64
USD 32,964 		100 -1.1% 329.64 USD 32,964
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
100 -1.1%
327.49
USD 32,749 		100 -1.1% 327.49 USD 32,749
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
100 -1.1%
326.34
USD 32,634 		100 -1.1% 326.34 USD 32,634
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
200 -2.1%
324.59
USD 64,918 		200 -2.1% 324.59 USD 64,918
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
200 -2.0%
323.65
USD 64,730 		200 -2.0% 323.65 USD 64,730
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
300 -3.0%
320.21
USD 96,063 		300 -3.0% 320.21 USD 96,063
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
200 -1.9%
314.74
USD 62,948 		200 -1.9% 314.74 USD 62,948
2025-03-05 2025-03-03 PS Planned sale

Huntsman Carole

Chief Commercial Officer

Officer
71 -0.7%
313.08
USD 22,229 		71 -0.7% 313.08 USD 22,229
2025-03-04 2025-02-28 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
175 -4.5%
341.55
USD 59,771 		175 -4.5% 341.55 USD 59,771
2025-03-04 2025-02-28 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,052 -21.2%
340.99
USD 358,717 		1,052 -21.2% 340.99 USD 358,717
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
216 -10.2%
360.07
USD 77,774 		216 -10.2% 360.07 USD 77,774
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
2,024 -48.7%
359.21
USD 727,042 		2,024 -48.7% 359.21 USD 727,042
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
3,548 -46.1%
358.33
USD 1,271,359 		3,548 -46.1% 358.33 USD 1,271,359
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
2,038 -20.9%
357.27
USD 728,109 		2,038 -20.9% 357.27 USD 728,109
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
2,791 -22.3%
356.51
USD 995,016 		2,791 -22.3% 356.51 USD 995,016
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
8,545 -40.5%
355.08
USD 3,034,150 		8,545 -40.5% 355.08 USD 3,034,150
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
238 -1.1%
353.83
USD 84,213 		238 -1.1% 353.83 USD 84,213
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
500 -2.3%
351.99
USD 175,995 		500 -2.3% 351.99 USD 175,995
2025-02-28 2025-02-27 S Sale

BATE KENNETH

Non-Executive Director
100 -0.5%
351.01
USD 35,101 		100 -0.5% 351.01 USD 35,101
2025-02-28 2025-02-27 S Sale

Daly James M

Non-Executive Director
770 -28.7%
348.94
USD 268,686 		770 -28.7% 348.94 USD 268,686
2025-02-28 2025-02-27 S Sale

Daly James M

Non-Executive Director
14,302 -84.2%
347.39
USD 4,968,372 		14,302 -84.2% 347.39 USD 4,968,372
2025-02-28 2025-02-27 S Sale

Daly James M

Non-Executive Director
398 -2.3%
346.90
USD 138,067 		398 -2.3% 346.90 USD 138,067
2025-01-27 2025-01-24 S Sale

Huntsman Carole

Chief Commercial Officer

Officer
347 -3.2%
335.24
USD 116,328 		347 -3.2% 335.24 USD 116,328
2025-01-27 2025-01-24 S Sale

Sibold William John

President and CEO

Executive Director
1,584 -2.8%
335.24
USD 531,020 		1,584 -2.8% 335.24 USD 531,020
2025-01-27 2025-01-24 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
103 -2.0%
335.24
USD 34,530 		103 -2.0% 335.24 USD 34,530
2025-01-27 2025-01-24 S Sale

Taub Rebecca

Pres., R&D, and CMO

Executive Director
648 -0.1%
335.24
USD 217,236 		648 -0.1% 335.24 USD 217,236
2025-01-17 2025-01-17 S Sale

Kelley Shannon T

General Counsel

Officer
277 -3.5%
273.41
USD 75,735 		277 -3.5% 273.41 USD 75,735
2025-01-17 2025-01-17 S Sale

Taub Rebecca

Pres., R&D, and CMO

Executive Director
1,689 -0.4%
273.41
USD 461,789 		1,689 -0.4% 273.41 USD 461,789
2025-01-17 2025-01-17 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
442 -8.0%
273.41
USD 120,847 		442 -8.0% 273.41 USD 120,847
2024-12-05 2024-12-03 S Sale

CRAVES FRED B

Non-Executive Director
520 -4.5%
315.90
USD 164,270 		520 -4.5% 315.90 USD 164,270
2024-12-05 2024-12-03 S Sale

CRAVES FRED B

Non-Executive Director
3,080 -21.1%
315.21
USD 970,852 		3,080 -21.1% 315.21 USD 970,852
2024-11-27 2024-11-25 S Sale

CRAVES FRED B

Non-Executive Director
1,200 -7.6%
350.71
USD 420,858 		1,200 -7.6% 350.71 USD 420,858
2024-11-27 2024-11-25 S Sale

CRAVES FRED B

Non-Executive Director
2,200 -12.2%
350.08
USD 770,171 		2,200 -12.2% 350.08 USD 770,171
2024-11-22 2024-11-21 S Sale

Huntsman Carole

Chief Commercial Officer

Officer
688 -6.0%
316.92
USD 218,041 		688 -6.0% 316.92 USD 218,041
2024-11-08 2024-11-07 PS Planned sale

Levy Richard S

Non-Executive Director
5,000 -31.2%
350.00
USD 1,750,000 		5,000 -31.2% 350.00 USD 1,750,000
2024-11-05 2024-11-01 PS Planned sale

Levy Richard S

Non-Executive Director
300 -2.7%
304.29
USD 91,287 		300 -2.7% 304.29 USD 91,287
2024-11-05 2024-11-01 PS Planned sale

Levy Richard S

Non-Executive Director
800 -6.6%
302.25
USD 241,799 		800 -6.6% 302.25 USD 241,799
2024-11-05 2024-11-01 PS Planned sale

Levy Richard S

Non-Executive Director
1,100 -8.3%
301.22
USD 331,339 		1,100 -8.3% 301.22 USD 331,339
2024-11-05 2024-11-01 PS Planned sale

Levy Richard S

Non-Executive Director
2,800 -17.5%
300.10
USD 840,278 		2,800 -17.5% 300.10 USD 840,278
2024-09-11 2024-09-09 S Sale

Sibold William John

President and CEO

Executive Director
6,363 -10.2%
243.83
USD 1,551,490 		6,363 -10.2% 243.83 USD 1,551,490
2024-06-18 2024-06-14 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,900 -25.7%
280.00
USD 532,000 		1,900 -25.7% 280.00 USD 532,000
2024-06-14 2024-06-12 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
2,000 -26.7%
285.00
USD 570,000 		2,000 -26.7% 285.00 USD 570,000
2024-05-23 2024-05-21 S Sale

Waltermire Robert E.

Senior VP, Chief Pharma Dev.

Officer
1,036 -15.9%
231.34
USD 239,668 		1,036 -15.9% 231.34 USD 239,668
2024-05-16 2024-05-14 PS Planned sale

CRAVES FRED B

Non-Executive Director
100 -0.0%
219.90
USD 21,990 		100 -0.0% 219.90 USD 21,990
2024-05-16 2024-05-14 PS Planned sale

CRAVES FRED B

Non-Executive Director
1,000 -0.2%
218.99
USD 218,995 		1,000 -0.2% 218.99 USD 218,995
2024-05-16 2024-05-14 PS Planned sale

CRAVES FRED B

Non-Executive Director
1,100 -0.3%
217.86
USD 239,641 		1,100 -0.3% 217.86 USD 239,641
2024-05-16 2024-05-14 PS Planned sale

CRAVES FRED B

Non-Executive Director
721 -0.2%
216.98
USD 156,445 		721 -0.2% 216.98 USD 156,445
2024-05-16 2024-05-14 PS Planned sale

CRAVES FRED B

Non-Executive Director
375 -0.1%
216.08
USD 81,031 		375 -0.1% 216.08 USD 81,031
// ... existing code ... // ... rest of the file ...